Valeant Pharmaceuticals Completes Syndication Of Incremental Term Loans

Jun 14, 2012, 18:30 ET from Valeant Pharmaceuticals International, Inc.

MONTREAL, June 14, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today the successful syndication of $600 million of incremental term loans under its existing senior secured credit facilities to be used to fund repayment of amounts outstanding under its existing $275 million revolving facility and for general corporate purposes, including acquisitions.  The incremental term loans will mature in 2019 and have terms that are similar to the Company's existing $600 million Term Loan B facility, with certain modifications. The facility closed on June 14, 2012.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

 

SOURCE Valeant Pharmaceuticals International, Inc.



RELATED LINKS

http://www.valeant.com
http://www.valeant.com